PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12234621-0 2002 Cyclic AMP differentially modulates CD40L expression on human nai;ve and memory CD4(+) T cells. Cyclic AMP 0-10 CD40 ligand Homo sapiens 36-41 12960288-0 2003 Divergence in NK cell and cyclic AMP regulation of T cell CD40L expression in asthmatic subjects. Cyclic AMP 26-36 CD40 ligand Homo sapiens 58-63 12960288-3 2003 Here, we demonstrate that cyclic adenosine monophosphate (cAMP) and beta-adrenoceptor agonists differentially regulate CD40L in asthma. Cyclic AMP 26-56 CD40 ligand Homo sapiens 119-124 12960288-3 2003 Here, we demonstrate that cyclic adenosine monophosphate (cAMP) and beta-adrenoceptor agonists differentially regulate CD40L in asthma. Cyclic AMP 58-62 CD40 ligand Homo sapiens 119-124 12960288-4 2003 cAMP increased naive T cell CD40L expression in asthmatics (9.8+/-8.5 increase in percent CD40L-positive cells), and expression in control subjects was inhibited (7.1+/-6.0 decrease in percent CD40L-positive cells; P< 0.05). Cyclic AMP 0-4 CD40 ligand Homo sapiens 28-33 12960288-4 2003 cAMP increased naive T cell CD40L expression in asthmatics (9.8+/-8.5 increase in percent CD40L-positive cells), and expression in control subjects was inhibited (7.1+/-6.0 decrease in percent CD40L-positive cells; P< 0.05). Cyclic AMP 0-4 CD40 ligand Homo sapiens 90-95 12960288-4 2003 cAMP increased naive T cell CD40L expression in asthmatics (9.8+/-8.5 increase in percent CD40L-positive cells), and expression in control subjects was inhibited (7.1+/-6.0 decrease in percent CD40L-positive cells; P< 0.05). Cyclic AMP 0-4 CD40 ligand Homo sapiens 90-95 12960288-5 2003 Cell depletion and reconstitution experiments were used to determine that cAMP enhancement of CD40L required cell-to-cell contact with an asthma-associated natural killer (NK) cell subset. Cyclic AMP 74-78 CD40 ligand Homo sapiens 94-99 12960288-7 2003 Our findings suggest that a subset of NK cells with elevated CD95 expression is associated with asthma and can reverse cAMP inhibitory effects on T cell CD40L with the potential to increase disease exacerbation. Cyclic AMP 119-123 CD40 ligand Homo sapiens 153-158 12234621-2 2002 In this study, we investigated CD40 ligand (CD40L) regulation by cyclic AMP (cAMP) and prostaglandin E(2) (PGE(2)) and observed differential effects depending upon the cell subset and mode of activation. Cyclic AMP 65-75 CD40 ligand Homo sapiens 31-42 12234621-2 2002 In this study, we investigated CD40 ligand (CD40L) regulation by cyclic AMP (cAMP) and prostaglandin E(2) (PGE(2)) and observed differential effects depending upon the cell subset and mode of activation. Cyclic AMP 65-75 CD40 ligand Homo sapiens 44-49 10087189-0 1999 Regulation of CD40L expression by cyclic AMP: contrasting proinflammatory and inhibitory actions. Cyclic AMP 34-44 CD40 ligand Homo sapiens 14-19 10087189-3 1999 Cyclic AMP was found to either inhibit or markedly increase CD40L expression dependent upon the mechanisms of T cell activation. Cyclic AMP 0-10 CD40 ligand Homo sapiens 60-65 10087189-4 1999 Cyclic AMP inhibited CD40L expression induced by TCR activation. Cyclic AMP 0-10 CD40 ligand Homo sapiens 21-26 7536930-5 1995 Sp-cAMPS, an analogue of cAMP, augmented CD40L and suppressed surface IgM-mediated activation. Cyclic AMP 3-7 CD40 ligand Homo sapiens 41-46 11985663-0 2002 Endothelial cell and cAMP regulation of T-cell CD40 ligand: relevance of calcium/calmodulin-dependent kinase IV signalling. Cyclic AMP 21-25 CD40 ligand Homo sapiens 47-58 11985663-2 2002 Because increased CD40L has been associated with myocardial infarction, effects of endothelial cells and cAMP with respect to CD40L regulation may be of clinical relevance. Cyclic AMP 105-109 CD40 ligand Homo sapiens 126-131 11985663-5 2002 Although it has previously been recognized that human endothelial cells can increase T-cell CD40L, this is the first description of the difference in responses of naive and memory cells and the first demonstration of synergistic effects of endothelial cells and cAMP on CD40L regulation. Cyclic AMP 262-266 CD40 ligand Homo sapiens 270-275 11985663-8 2002 Endothelial cell costimulation of CD40L was found to be dependent upon calcineurin activity while cAMP actions to increase CD40L were dependent upon CaMKIV. Cyclic AMP 98-102 CD40 ligand Homo sapiens 123-128 11985663-10 2002 These data indicate that endothelial cell costimulation can interact with cAMP through calcium signalling pathways to synergistically enhance CD40L expression. Cyclic AMP 74-78 CD40 ligand Homo sapiens 142-147 10929069-0 2000 Induction of functional CD154 (CD40 ligand) in neonatal T cells by cAMP-elevating agents. Cyclic AMP 67-71 CD40 ligand Homo sapiens 24-29 10929069-0 2000 Induction of functional CD154 (CD40 ligand) in neonatal T cells by cAMP-elevating agents. Cyclic AMP 67-71 CD40 ligand Homo sapiens 31-42 10929069-2 2000 In the present report we describe that CD45RA+ newborn cells are able to synthesize and express CD154 at similar or even higher levels than adult cells in response to ionomycin and cAMP-elevating agents which trigger the protein kinase A (PKA) -mediated metabolic pathway. Cyclic AMP 181-185 CD40 ligand Homo sapiens 96-101 10929069-5 2000 Surface levels of CD154 did not correlate with specific mRNA concentration, indicating that dibutyryl cAMP up-regulates CD154 by acting at a post-transcriptional stage. Cyclic AMP 102-106 CD40 ligand Homo sapiens 18-23 10929069-5 2000 Surface levels of CD154 did not correlate with specific mRNA concentration, indicating that dibutyryl cAMP up-regulates CD154 by acting at a post-transcriptional stage. Cyclic AMP 102-106 CD40 ligand Homo sapiens 120-125 10087189-5 1999 In contrast, cAMP enhanced CD40L induced by CD2-mediated T cell activation or by calcium-dependent mechanisms. Cyclic AMP 13-17 CD40 ligand Homo sapiens 27-32 10087189-6 1999 While neither CD28 costimulation nor exogenous IL-2 or IL-4 prevented cAMP inhibition in TCR activated cells, addition of calcium ionophore to TCR activation prevented any inhibitory effects and caused cAMP to increase CD40L expression. Cyclic AMP 202-206 CD40 ligand Homo sapiens 219-224 10087189-7 1999 Actions of cAMP to increase CD40L expression appeared independent of PKC and were not a reflection of generalized cellular activation since neither CD25 nor CD69 expression was affected. Cyclic AMP 11-15 CD40 ligand Homo sapiens 28-33 10087189-8 1999 The markedly contrasting actions of cAMP to decrease or increase CD40L expression, an important control point in the immune response, could be relevant to actions of commonly used medications including bronchodilators. Cyclic AMP 36-40 CD40 ligand Homo sapiens 65-70 33834609-9 2021 The resistance to cAMP signalling was also observed for CD154 and CD63 expression. Cyclic AMP 18-22 CD40 ligand Homo sapiens 56-61